Wide-spectrum characterization of trabectedin: biology, clinical activity and future perspectives (Q37760957)

22 August 2017

1 reference

title

Wide-spectrum characterization of trabectedin: biology, clinical activity and future perspectives (English)

1 reference

22 August 2017

2

1 reference

22 August 2017

5

Daniele Santini

1 reference

22 August 2017

6

Giuseppe Tonini

1 reference

22 August 2017

1

Bruno Vincenzi

1 reference

22 August 2017

4

Gaia Schiavon

1 reference

22 August 2017

3

Anna Maria Frezza

1 reference

22 August 2017

1 June 2010

1 reference

22 August 2017

1 reference

22 August 2017

11

1 reference

22 August 2017

6

1 reference

22 August 2017

865-878

1 reference

Antitumor compounds from tunicates

22 August 2017

1 reference

Enantioselective Total Synthesis of Ecteinascidin 743

21 January 2018

1 reference

Development of Yondelis (trabectedin, ET-743). A semisynthetic process solves the supply problem.

21 January 2018

1 reference

Synthesis of Natural Ecteinascidins (ET-729, ET-745, ET-759B, ET-736, ET-637, ET-594) from Cyanosafracin B

21 January 2018

1 reference

Synthetic studies toward ecteinascidin 743.

21 January 2018

1 reference

Stereospecific formal total synthesis of ecteinascidin 743.

21 January 2018

1 reference

Synthetic studies on Et-743. Assembly of the pentacyclic core and a formal total synthesis

21 January 2018

1 reference

Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin

21 January 2018

1 reference

DNA and non-DNA targets in the mechanism of action of the antitumor drug trabectedin.

21 January 2018

1 reference

Additional antitumor ecteinascidins from a Caribbean tunicate: crystal structures and activities in vivo

21 January 2018

1 reference

DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata

21 January 2018

1 reference

Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove

21 January 2018

1 reference

Interaction of an alkylating camptothecin derivative with a DNA base at topoisomerase I-DNA cleavage sites

21 January 2018

1 reference

Differential rates of reversibility of ecteinascidin 743-DNA covalent adducts from different sequences lead to migration to favored bonding sites

21 January 2018

1 reference

Poisoning of human DNA topoisomerase I by ecteinascidin 743, an anticancer drug that selectively alkylates DNA in the minor groove

21 January 2018

1 reference

Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action.

21 January 2018

1 reference

A 3.(ET743)-DNA complex that both resembles an RNA-DNA hybrid and mimicks zinc finger-induced DNA structural distortions.

21 January 2018

1 reference

Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743.

21 January 2018

1 reference

Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation

21 January 2018

1 reference

Isolation and characterization of an IGROV-1 human ovarian cancer cell line made resistant to Ecteinascidin-743 (ET-743).

21 January 2018

1 reference

Transcriptional inhibition of type I collagen gene expression in scleroderma fibroblasts by the antineoplastic drug ecteinascidin 743.

21 January 2018

1 reference

Ecteinascidin-743 drug resistance in sarcoma cells: transcriptional and cellular alterations

21 January 2018

1 reference

Characterisation of antimitotic products from marine organisms that disorganise the microtubule network: ecteinascidin 743, isohomohalichondrin-B and LL-15.

21 January 2018

1 reference

The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux

21 January 2018

1 reference

Humanized xenobiotic response in mice expressing nuclear receptor SXR.

21 January 2018

1 reference

Antitumor activity- and gene expression-based profiling of ecteinascidin Et 743 and phthalascidin Pt 650.

21 January 2018

1 reference

Molecular characterisation of two human cancer cell lines selected in vitro for their chemotherapeutic drug resistance to ET-743.

21 January 2018

1 reference

Selective effects of the anticancer drug Yondelis (ET-743) on cell-cycle promoters

21 January 2018

1 reference

Differential cytostatic and apoptotic effects of ecteinascidin-743 in cancer cells. Transcription-dependent cell cycle arrest and transcription-independent JNK and mitochondrial mediated apoptosis.

21 January 2018

1 reference

Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair.

21 January 2018

1 reference

The inefficiency of incisions of ecteinascidin 743-DNA adducts by the UvrABC nuclease and the unique structural feature of the DNA adducts can be used to explain the repair-dependent toxicities of this antitumor agent

21 January 2018

1 reference

Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways

21 January 2018

1 reference

Dynamics of cell cycle phase perturbations by trabectedin (ET-743) in nucleotide excision repair (NER)-deficient and NER-proficient cells, unravelled by a novel mathematical simulation approach.

21 January 2018

1 reference

Von Hippel-Lindau-coupled and transcription-coupled nucleotide excision repair-dependent degradation of RNA polymerase II in response to trabectedin

21 January 2018

1 reference

Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743.

21 January 2018

1 reference

Transcription-coupled DNA double-strand breaks are mediated via the nucleotide excision repair and the Mre11-Rad50-Nbs1 complex

21 January 2018

1 reference

Role of homologous recombination in trabectedin-induced DNA damage

21 January 2018

1 reference

Relevance of the Fanconi anemia pathway in the response of human cells to trabectedin

21 January 2018

1 reference

DNA damage responses and their many interactions with the replication fork

21 January 2018

1 reference

Search for metabolites of ecteinascidin 743, a novel, marine-derived, anti-cancer agent, in man.

21 January 2018

1 reference

Metabolism of trabectedin (ET-743, Yondelis) in patients with advanced cancer

21 January 2018

1 reference

Trabectedin (Yondelis, formerly ET-743), a mass balance study in patients with advanced cancer.

21 January 2018

1 reference

In-vitro cytotoxicity of ET-743 (Trabectedin, Yondelis), a marine anti-cancer drug, in the Hep G2 cell line: influence of cytochrome P450 and phase II inhibition, and cytochrome P450 induction

21 January 2018

1 reference

In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis, Trabectidin), a novel marine anti-cancer drug

21 January 2018

1 reference

Pulse corticosteroid therapy with methylprednisolone or dexamethasone

21 January 2018

1 reference

Evaluation of Chronic Dietary Exposure to Indole-3-Carbinol and Absorption-Enhanced 3,3'-Diindolylmethane in Sprague-Dawley Rats

21 January 2018

1 reference

Dietary agent indole-3-carbinol protects female rats against the hepatotoxicity of the antitumor drug ET-743 (trabectidin) without compromising efficacy in a rat mammary carcinoma

21 January 2018

1 reference

Comparison of four modulators of drug metabolism as protectants against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the female rat and in hepatocytes in vitro

21 January 2018

1 reference

Modulation of trabectedin (ET-743) hepatobiliary disposition by multidrug resistance-associated proteins (Mrps) may prevent hepatotoxicity

21 January 2018

1 reference

Population pharmacokinetic meta-analysis of trabectedin (ET-743, Yondelis) in cancer patients.

21 January 2018

1 reference

Semimechanistic pharmacokinetic/pharmacodynamic model for hepatoprotective effect of dexamethasone on transient transaminitis after trabectedin (ET-743) treatment

21 January 2018

1 reference

Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of trabectedin (ET-743, Yondelis) induced neutropenia.

21 January 2018

1 reference

In vitro toxicity of three new antitumoral drugs (trabectedin, aplidin, and kahalalide F) on hematopoietic progenitors and stem cells

21 January 2018

1 reference

Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production

21 January 2018

1 reference

Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma.

21 January 2018

1 reference

Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients

21 January 2018

1 reference

Fatal rhabdomyolysis as a complication of ET-743 (Yondelis) chemotherapy for sarcoma

21 January 2018

1 reference

Recognition of a new chemotherapeutic vesicant: trabectedin (ecteinascidin-743) extravasation with skin and soft tissue damage.

21 January 2018

1 reference

In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients

21 January 2018

1 reference

High antitumour activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer

21 January 2018

1 reference

Transcriptional signature of Ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemo-naive patients.

21 January 2018

1 reference

Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors

21 January 2018

1 reference

The combination of yondelis and cisplatin is synergistic against human tumor xenografts

21 January 2018

1 reference

Combination of trabectedin and irinotecan is highly effective in a human rhabdomyosarcoma xenograft

21 January 2018

1 reference

Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies

21 January 2018

1 reference

In vitro interaction between ecteinascidin 743 (ET-743) and radiation, in relation to its cell cycle effects

21 January 2018

1 reference

In vitro radiosensitisation by trabectedin in human cancer cell lines.

21 January 2018

1 reference

Trabectedin (ET-743, Yondelis) is a substrate for P-glycoprotein, but only high expression of P-glycoprotein confers the multidrug resistance phenotype

21 January 2018

1 reference

Diverse cross-resistance phenotype to ET-743 and PM00104 in multi-drug resistant cell lines.

21 January 2018

1 reference

Wild type p53 sensitizes soft tissue sarcoma cells to doxorubicin by down-regulating multidrug resistance-1 expression

21 January 2018

1 reference

ZNF93 increases resistance to ET-743 (Trabectedin; Yondelis) and PM00104 (Zalypsis) in human cancer cell lines

21 January 2018

1 reference

Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors.

21 January 2018

1 reference

Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity

21 January 2018

1 reference

Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study

21 January 2018

1 reference

Phase I and pharmacokinetic study of trabectedin as a 1- or 3-hour infusion weekly in patients with advanced solid malignancies.

21 January 2018

1 reference

A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies

21 January 2018

1 reference

Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors.

21 January 2018

1 reference

Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma

21 January 2018

1 reference

Phase I clinical and pharmacokinetic study of trabectedin and cisplatin in solid tumours.

21 January 2018

1 reference

Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer.

21 January 2018

1 reference

Ecteinascidin-743: evidence of activity in advanced, pretreated soft tissue and bone sarcoma patients

21 January 2018

1 reference

Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study

21 January 2018

1 reference

Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series.

21 January 2018

1 reference

Activity of trabectedin (ET-743, Yondelis) in metastatic uterine leiomyosarcoma

21 January 2018

1 reference

Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy.

21 January 2018

1 reference

Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial

21 January 2018

1 reference

Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study

21 January 2018

1 reference

Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules

21 January 2018

1 reference

Experience of the use of trabectedin (ET-743, Yondelis) in 21 patients with pre-treated advanced sarcoma from a single centre

21 January 2018

1 reference

Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails.

21 January 2018

1 reference

A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens

21 January 2018

1 reference

Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer.

21 January 2018

1 reference

Single-agent trabectedin as second-line therapy of persistent or recurrent endometrial cancer: results of a multicenter phase II study.

21 January 2018

1 reference

A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer

21 January 2018

1 reference

A phase II and pharmacokinetic study of ecteinascidin 743 in patients with gastrointestinal stromal tumors.

21 January 2018

1 reference

A phase II study of ET-743/trabectedin ('Yondelis') for patients with advanced gastrointestinal stromal tumours

21 January 2018

1 reference

Tuberin haploinsufficiency is associated with the loss of OGG1 in rat kidney tumors

21 January 2018

1 reference

Further Insight into the DNA Recognition Mechanism of Trabectedin from the Differential Affinity of Its Demethylated Analogue Ecteinascidin ET729 for the Triplet DNA Binding Site CGA

21 January 2018

1 reference

Increased DNA Binding Specificity for Antitumor Ecteinascidin 743 through Protein−DNA Interactions?

21 January 2018

1 reference

Extreme sensitivity to Yondelis® (Trabectedin, ET-743) in low passaged sarcoma cell lines correlates with mutated p53

21 January 2018

1 reference

Phase II Study of Trabectedin in Pretreated Patients with Advanced Colorectal Cancer

21 January 2018

1 reference

Safracins, new antitumor antibiotics. I. Producing organism, fermentation and isolation

21 January 2018

1 reference

12 April 2024

https://opencitations.net/index/api/v1/citations/10.7164/ANTIBIOTICS.36.1279

Identifiers

DOI

10.2217/PGS.10.69

1 reference

22 August 2017

1 reference

PubMed ID

20504257